BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from its Phase 3 program for the selective NaV1.8 inhibitor, VX-548, in the treatment of moderate-to-severe acute pain. The Phase 3 program included two randomized, double-blind, placebo-controlled, pivotal trials, one following abdominoplasty surgery and one following bunionectomy surgery, as well as a single arm safety and effectiveness study which enrolled patients with a broad range of surgical a ...

In the latest market close, Vertex Pharmaceuticals (VRTX) reached $435.82, with a +1.31% movement compared to the previous day. This change outpaced the S&P 500's 0.76% gain on the day. Elsewhere, the Dow gained 0.59%, while the tech-heavy Nasdaq added 1.12%.Shares of the drugmaker have appreciated by 5.72% over the course of the past month, outperforming the Medical sector's gain of 1.57% and the S&P 500's gain of 2.5%.The upcoming earnings release of Vertex Pharmaceuticals will be of great interest to inv ...

I'll readily admit that I've picked some supposed growth stocks in the past that didn't deliver much growth. The good news, though, is that my winners have far outpaced my losers over the long run.One of my mistakes has been to rely on wishful thinking. I've bought stocks that had potential but weren't anywhere close to being profitable yet and had valuations that weren't easily justified. A smarter approach, based on my experience, is to insist on potential, profits, and a reasonable price tag. My top grow ...

Those who put money in Vertex Pharmaceuticals (VRTX 0.57%) 10 years ago are sitting pretty right now. The company has easily outpaced the market over this period.However, a lot has changed for the biotech in the meantime, and as we all know, past success isn't a guarantee of anything. Can Vertex pull off another market-beating performance through the next decade? Let's dig into what's going on with the biotech and determine where it might be in 10 years. Vertex's core area is still a growth driverIn the pas ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Vertex Pharmaceuticals (VRTX) .Vertex currently has an average br ...

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $439.70, moving -0.09% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of 0.29%. On the other hand, the Dow registered a loss of 0.25%, and the technology-centric Nasdaq increased by 0.43%.The drugmaker's shares have seen an increase of 8.6% over the last month, surpassing the Medical sector's gain of 2.29% and the S&P 500's gain of 2.08%.Market participants will be closely following the finan ...

Vertex Pharmaceuticals (VRTX) ended the recent trading session at $433.76, demonstrating a -0.85% swing from the preceding day's closing price. The stock fell short of the S&P 500, which registered a loss of 0.56% for the day. Meanwhile, the Dow lost 0.25%, and the Nasdaq, a tech-heavy index, lost 0.59%.Shares of the drugmaker have appreciated by 8.52% over the course of the past month, outperforming the Medical sector's gain of 3.8% and the S&P 500's gain of 1.2%.Analysts and investors alike will be keepin ...

Vertex Pharmaceuticals (VRTX) , along with CRISPR Therapeutics (CRSP) , announced that the FDA expanded the label of their one-shot gene therapy Casgevy to treat transfusion-dependent beta thalassemia (TDT) in patients aged 12 years and older.The approval comes just a month after the FDA approved the therapy for sickle cell disease (SCD) in the same age group. Following this initial approval, Casgevy became the first gene therapy utilizing the Nobel prize-winning CRISPR technology. This technology can selec ...

About this content About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business outpu ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration (FDA) has approved CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited cell therapy, for the treatment of transfusion-dependent beta thalassemia (TDT) in patients 12 years and older. “ On the heels of the historic FDA approval of CASGEVY for sickle cell disease, it is exciting to now secure approval for TDT well ahead of the PDUFA date,” said Reshma Kew ...